• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Clearside Biomedical names McElheny as biz dev veep | Personnel Moves, Nov. 8, 2016

November 8, 2016 By Sarah Faulkner

Clearside Biomedical names VP business development | Personnel Moves, Nov. 8, 2016Clearside Biomedical (NSDQ:CLSD) today named Rick McElheny as its VP of business development.

The Alpharetta, Ga.-based company is developing a microinjector loaded with CLS-TA (triamcinolone acetonide) to treat macular edema. The device is designed to inject the compound in the a 30-µm gap between the choroid and the sclera, called the suprachoroidal space. A pivotal Phase III trial of the treatment is under way.

Before his role at Clearside, McElheny served as senior VP of corporate development at Sarvint. He also founded and served as VP of corporate development & supply chain at Vidara Therapeutics. He also held positions at Meda Pharmaceuticals, Schering-Plough, and Johnson & Johnson.

As VP of business development at Clearside, McElheny will work to continue existing collaborations and establish new ones for the company’s product candidates and programs.

“I am delighted to have someone with Rick’s caliber join the Clearside team to build out future collaborations with innovative companies as we seek to develop transformative, elegant, precise solutions to restore and preserve vision,” president & CEO Daniel White, said in prepared remarks. “Rick is an accomplished professional in developing partnerships that enhance shareholder value and I am confident he will do the same at Clearside.”

Earlier this year, the company raised $50 million with its initial public offering, floating 7.2 million shares at $7 apiece. CLSD shares were trading at $16.81 apiece in mid-afternoon trading, up 2%.

Filed Under: Drug-Device Combinations, Featured, Optical/Ophthalmic, Personnel Tagged With: Clearside Biomedical, johnsonandjohnson

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS